Cumberland Pharmaceuticals Announces New Program To Develop Vasculan™ For Systemic Sclerosis The U.S. Food and Drug Administration (FDA) has cleared Cumberland's investigational new drug application (IND) for Phase II clinical program for Vasculan™ in patients with systemic sclerosis. Cumberland Pharmaceuticals, 04/27/2016. (Also see Scleroderma Clinical Trials)
Corbus Pharmaceuticals Receives FDA Approval for Open–Label Extension to Its Phase 2 Trial of Resunab for Systemic Sclerosis. Corbus Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted approval for a 12–month open–label extension study of the ongoing Phase 2 clinical trial of Resunab™ for the treatment of diffuse cutaneous systemic sclerosis. Corbus Pharmaceuticals, 04/12/16. (Also see Scleroderma Clinical Trials)
Impact of pulmonary fibrosis (PF) and elevated pulmonary pressures (PHT) on right ventricular (RV) function in patients with systemic sclerosis (SSc). SSc patients show impaired RV function and both pulmonary fibrosis and PHT are independently associated with RV dysfunction. PubMed, Rheumatology (Oxford),2016 Mar;55(3):504-12. (Also see Cardiac (Heart) Involvement and Pulmonary Hypertension)
Research of Lung Fibrosis in Scleroderma (SSc) Reveals High Levels of Antibodies That Correlate with Disease Progression. Circulating antibodies against specific chemokine receptors exist in higher levels in patients with SSc and these antibodies correlate with disease progression and clinical manifestations of the disease. Scleroderma News, 02/25/2016. (Also see Pulmonary Fibrosis)
For Systemic Sclerosis Manifestations in Face and Hands, Fat and Stromal Vascular Fraction Appears Promising. It was suggested that fat and stromal vascular fraction injections (a minimally invasive procedure) are an efficient treatment strategy for systemic sclerosis patients. Scleroderma News, 02/24/2016. (Also see Musculoskeletal Involvement)
Impaired angiogenesis as a feature of digital ulcers (DU) in systemic sclerosis. Our study confirmed the relationship between angiogenic vascular biomarkers and the occurrence of DU. PubMed, Clin Rheumatol, 02/26/2016. (Also see Digital Ulcers)
At–risk systemic sclerosis (SSc) patients can be identified using nailfold videocapillaroscopy ( NVC) a non–invasive imaging technique. The results supported the use of NVC as a routine strategy to evaluate patients with systemic sclerosis and to identify those at higher risks of disease progression and severity. Scleroderma News, 03/08/2016. (Also see Nailfold Videocapillaroscopy)
The investigation of killer cell immunoglobulin–like receptor (KIR) genotyping in patients with systemic lupus erytematosus (SLE) and systemic sclerosis (SSc). The variations of some KIR genes may have a role in the pathogenesis of SLE and SSc and may cause major organ involvement in SLE. PubMed, Clin Rheumatol, 03/09/2016. (Also see Causes of Scleroderma: Natural Killer Cells)
Cellular Therapies in Systemic Sclerosis: Recent Progress. Currently, hematopoietic stem cell transplantation is the only cellular therapy that has demonstrated clinical effects on the immune system, neoangiogenesis, and fibrosis. PubMed, Curr Rheumatol Rep, 2016 Feb;18(2):12. (Also see Stem Cell (Bone Marrow) Transplantation)
Quantitative volumetric assessment of pulmonary involvement in patients with systemic sclerosis (SSc). The percentage of lower lobe volume (PLLV) of the right lung may decrease in SSc patients with interstitial lung disease and the PLLV may be a quantitative parameter indicating damage in the lung. Quantitative Imaging in Medicine and Surgery, 03/09/2016. (Also see Diagnosis of Scleroderma Pulmonary Involvement)
Toll–like receptor 9 (TLR9) signaling is augmented in systemic sclerosis (SSc) and elicits transforming growth factor–ß (TGF–ß)–dependent fibroblast activation. In patients with SSc, mitochondrialDNA and other damage–associated TLR9 ligands in the skin might trigger localized activation of TLR9 signaling, TGF–ß production and consequent fibroblast activation. PubMed, Arthritis Rheumatol, 03/04/2016. (Also see Causes of Scleroderma: Fibroblasts)
Targeting microRNA (miR)–155 to Treat Experimental Scleroderma. Our data suggest the potential of miR–155 silencing as a promising treatment for dermal fibrosis, especially in topical applications. PubMed, Sci Rep, 2016 Feb 1;6:20314. (Also see Skin Fibrosis)
Reading Voices of Scleroderma Books: Diana Kramer.
Sharing Scleroderma Awareness Bracelets: Deb Martin, Brenda Miller, Vickie Risner.
Thanks to UNITED WAY donors of Central New Mexico and Snohomish County!
Patricia Ann Black: Marilyn Currier, Shelley Ensz, Richard Howitt, Gerald and Pat Ivanejko, Juno Beach Condo Association, Keith and Rosalyn Miller, and Elaine Wible.
Gayle Hedlin: Daniel and Joann Pepper and Nancy Smithberg.
Janet Paulmenn: Anonymous, Mary Jo Austin, Shelley Blaser, Susan Book, Dennis and Pat Clayton, Grace Cunha, Cindy Dorio, Michael and Patricia Donahue, Shelley Ensz, Nancy Falkenhagen, Jo Frowde, Alice Gigl, Margaret Hollywood, Karen Khalaf and Family, Susan Kvarantan, Bradley Lawrence, Jillyan Little, Donna Madge, Michele Maxson, Barry and Judith McCabe, John Moffett, My Tribute Foundation, Joan-Marie Permison, John Roberts, Margaret Roof, Maryellen Ryan, Mayalin and Kiralee Murphy, Nancy Settle-Murphy, and Bruce and Elizabeth Winter.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content.